DUBLIN, Ireland--(BUSINESS WIRE)--Elan Corporation, plc today announced its full-year and fourth quarter 2007 financial results and provided guidance for its financial outlook for 2008. Commenting on Elan’s business, Kelly Martin, Elan’s president and chief executive officer, said, “Our key operating principles of patient focus, disciplined execution, and delivery of tangible results and outcomes were achieved in 2007. The continued traction for Tysabri in MS and the approval for Crohn’s disease in the US; the advancement of our AD clinical programs for AAB-001 and ELND-005; and the on-going progress in our preclinical discovery efforts all provide a strong foundation to maintain and potentially increase our positive momentum in 2008. We remain completely committed to advancing our science for patients and clinicians around the world, increasing therapeutic options for those who are directly affected by chronic diseases such as Alzheimer’s, Parkinson’s, Multiple Sclerosis and Crohn’s.”
